Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
63,637.52 -2,726.73 (-4.11%) CMC Crypto 200
1,350.09 -32.48 (-2.35%)
Intellia Therapeutics, Inc. (NTLA)
Pre-market:
- Simply Wall St.
Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
- Zacks
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
- GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment
